Interní Med. 2002; 4(1): 19-22

Nová perorální antidiabetika mění strategii léčby diabetu

doc. MUDr. Milan Kvapil CSc
Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze

Keywords: therapy of diabetes, metabolic compensation, antidiabetic drugs.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvapil M. Nová perorální antidiabetika mění strategii léčby diabetu. Interní Med. 2002;4(1):19-22.

K dosažení optimální kompenzace u nemocných s diabetem 2. typu je třeba individualizovat terapii podle stádia nemoci a poměru základních patofyziologických poruch. Pozornost se soustřeďuje na hledání nových účinnějších postupů, ať již jsou realizovány novým použitím známých molekul perorálních antidiabetik, či zaváděním nových látek.

NEW ANTIDIABETIC DRUGS CHANGE THERAPEUTIC STRATEGY OF DIABETES

In order to get the optimal compensation of the type 2 diabetic patients it is necessery to adapt therapy according the disease stage and the parameters of basic pathophysiological abnormalites. At the present time the formulation of the more effective aproaches is the center of the current research, which is realised either new applicationof the known molecules of antidiabetic drugs, or by introduction of the new developed drugs.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alberti KGMM, Zimmet P, Defronzo RA. International Textbook of Diabetes Mellitus. Chichester: John Wiley and Sons Ltd. 1997; 1827 s.
    2. Allvoine TH, et al. Efficacy a fixed combination metformin/glibenclamide in metformin failure type 2 diabetes patients. Diabetes Res Clin Pract, 2000; 50, (Suppl 1): 1368. Go to original source...
    3. Dunn JC, Peters DH. Metformin. Drugs, 1995; 49: 721-749. Go to original source... Go to PubMed...
    4. Fonseca J, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA, 2000; 283: 1695-1702. Go to original source... Go to PubMed...
    5. Gribble FM, Ashcroft FM. Diferential sensitivity of betta-cell and extrapancreatic K channels to gliclazide. Diabetologia, 1999; 42: 845-848. Go to original source... Go to PubMed...
    6. Harrower A. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism, 2000; 49: Suppl 2, 7-11. Go to original source... Go to PubMed...
    7. Kvapil M, Pelikánová T, Škarpová O, Olšovský J, Kubátová H, Pichlerová D, Kárová R. Výsledky studie AGEE/DCD/080: multicentrická, randomizovaná, paralelní, dvojitě zaslepená, placebem kontrolovaná studie repaglinidu užívaného jak prandiální glukózový regulátor v léčbě pacientů s DM 2, dříve neléčených PAD. Abstrakta XXXV. Diabetologické dny v Luhačovicích, 15.-17. 4. 1999, 42.
    8. Matthews DR, et al. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia, 1999; 42, Suppl. 1, A228.
    9. Mosses RG, et al. Flexible meal-related dosing with repaglinide facilitates glycemic contol in therapy-naive type 2 diabetes. Diabetes Care, 2001; 24: 11-15. Go to original source... Go to PubMed...
    10. Perušičová J. (Eds) Diabetes mellitus 2. typu. 1. vydání, Praha: Galén, 1996.
    11. Pickup J, Williams G. Textbook of Diabetes, Blackwell Scientific Publications, Oxford 1991.
    12. UKPDS Group: Effect of intensive blood-glucose control with metformin on complications overweigt patients with type 2 diabetes. UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 854-865. Go to original source...
    13. Wiensperger NF. Metformin: Intrinsic vasculoprotective properties. Diabetes technology and Therapeutics, 2000; 2: 259-272. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.